Isracann Biosciences Inc. announces expansion of its leadership team
by CM Staff
Isracann wishes to introduce added leadership, in some instances, refocus the efforts of veteran team members into a new more efficiently focused leadership team for the remainder of 2022.
VANCOUVER — Isracann Biosciences Inc. announces that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately.
As Isracann moves from development to operations, and to try and accommodate the integration of natural health medicine (NHM) research and development to meet its near-term commercial goals for revenue generation this year, the Company wishes to introduce added leadership, in some instances, refocus the efforts of veteran team members into a new more efficiently focused Isracann leadership team for the remainder of 2022 and beyond.
Mr. James (JT) Thompson joins as Chief Operations Officer
Mr. Thompson is an experienced executive, dedicated to trying to build high-performance teams and cultures. He brings a background in strategic development and go-to-market execution, having previously dementated increased return on investment in operations and finance. Mr. Thompson has held multiple executive leadership positions across various industries providing a depth of experience and ability to drive operations forward efficiently.
Mr. Matt Chatterton moves to Chief Science Officer
The appointment of a new COO allows Mr. Chatterton to focus his efforts and expertise on the engagement and support of clinical studies, as well as oversee manufacturing processes including qualification and management of suppliers and vendors. He will also serve as principle contact and regulatory lead with the FDA & Health Canada and ensure good governance of patient surveys regarding initial efficacy studies with the Praesidio division health practitioners, including senior doctors and specialists.
Mr. Stephen Parker joins as VP of Business Development
Mr. Parker brings over twelve years of marketing, public relations, communications and sales experience in CPG, cannabis, and the alcoholic beverage sectors. Since 2018, he has led the sales, marketing and innovation teams at United Greeneries, a licensed producer in the legal Canadian cannabis marketplace. During this period, he and his team launched over 50 products into the market including the first ever infused topical in the national market. Prior to joining the cannabis industry, he worked as a consultant for a variety of companies including Frito-Lays, Canopy Growth Corporation, PepsiCo, and Molson-Coors.
Dr. George Vrabec, MD FRCSC (Urol.) joins as board director.
Dr. Vrabec is a Urologist and Surgeon with over 20 years of medical experience, as well as the Principal Investigator of Exdeo Clinical Research. He has conducted more than 30 clinical trials in a wide array of Urological diseases and has published studies in various journals, including the New England Journal of Medicine. Dr. Vrabec serves on multiple boards, including Fraser Valley Health Care Foundation.
The Company further advises that Mr. Darryl Jones has resigned from the board of directors and the Company thanks him for his diligent and timely efforts during the initial period of corporate development, including the turbulent pandemic years, and wishes him well on his future endeavours.
